Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutic Solutions International has filed a new patent indicating that QuadraMune may reduce cognitive decline linked to COVID-19, based on studies conducted on mice. The experiments demonstrated a significant preservation of cognitive activity and reduced neural inflammation in mice treated with various doses of QuadraMune. This nutraceutical aims to address the long-term brain impacts of COVID-19, as highlighted by its potential anti-inflammatory and neuroregenerative effects. CEO Timothy Dixon emphasized the urgent need for effective treatments given the worsening understanding of COVID-19's aftermath.
TSOI announced positive results from a pilot clinical trial of QuadraMune, involving 20 subjects. The study showed that a seven-day treatment with QuadraMune significantly reduced the inflammatory cytokine interleukin-6 production in response to SARS-CoV-2 spike protein. Additionally, TSOI received a patent allowance for QuadraMune's immune modulatory properties against COVID-19. Company representatives emphasized the supplement's unique ability to alter immune responses, raising potential synergy with existing vaccines as new variants emerge.
Therapeutic Solutions International (TSOI) reported successful treatment of 15 patients using the JadiCell™ adult stem cell product under the Right to Try Law. Notably, 12 COVID-19 patients showed profound recovery, and retired Navy SEALs exhibited significant improvement in biomarkers linked to Chronic Traumatic Encephalopathy (CTE). The company is advancing towards Phase III clinical trials for JadiCells, focusing on patient safety and treatment effectiveness amid ongoing COVID-19 challenges.
Therapeutic Solutions International has received a Notice of Allowance from the United States Patent and Trademark Office for its patent on QuadraMune®, a nutraceutical aimed at enhancing the immune system by inhibiting the indolamine 2,3 deoxygenase (IDO) pathway. This is a pioneering patent for a nutraceutical supplement in this area. The company aims to tap into the $15.2 billion checkpoint inhibitor market. Several ingredients in QuadraMune have shown potential anti-COVID effects, validated by independent universities after patent filing.
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) has initiated pilot batch production of JadiCells, its FDA-cleared umbilical cord stem cell product, set to enter Phase III clinical trials for COVID-19. The company successfully reproduced manufacturing protocols under US patent #9,803,176 B2 for various indications. This milestone aims to reduce production costs and enhance accessibility for healthcare providers. Enhanced internal manufacturing aligns with the anticipated demand driven by the Right to Try Law and Emergency Use Authorization.
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced lab data showing that exosomes from JadiCells™, the Company's Phase III COVID-19 therapy candidate, can inhibit neutrophil extracellular trap production. These traps are linked to inflammation in conditions such as COVID-19 and cancer. The findings support a patent application and suggest potential for new treatments for inflammation-related diseases. Dr. James Veltmeyer highlighted the rapid translation of this discovery into applications, while Timothy Dixon emphasized the opportunity for First in Class approaches for big pharma partnerships.
Therapeutic Solutions International (TSOI) highlighted their nutraceutical QuadraMune™, designed to enhance immunity against COVID-19. The company pointed to strong independent research backing its ingredients, such as Pterostilbene and Thymoquinone, which exhibit antiviral properties against SARS-CoV-2 and aid immune response. CEO Timothy Dixon emphasized the growing demand for natural therapies alongside new COVID-19 variants. QuadraMune™ stands out in the market due to its scientific validation, potentially positioning TSOI favorably for future developments in the immunomodulation space.
Therapeutic Solutions International (OTC Markets: TSOI) announced promising data and a new patent for a cellular therapy aimed at reducing lung injury and promoting lung regeneration. The research shows that combining T regulatory cells from umbilical cord blood with JadiCells effectively suppresses lung damage in experimental models. The findings suggest a molecular mechanism involving the GITR pathway that enhances therapy efficacy. The company is preparing to launch an FDA Phase III trial for COVID-19 patients while exploring additional molecular switches to improve stem cell activity.
Therapeutic Solutions International (OTC Markets: TSOI) announced promising new data indicating that its nutraceutical, QuadraMune™, enhances the effects of ivermectin in animal models mimicking COVID-19. The study revealed that while ivermectin had a minimal impact on lung inflammation, combining it with QuadraMune™ significantly improved outcomes by stimulating natural killer (NK) cells. The company is exploring combination trials between these treatments and emphasizes the findings' potential clinical implications.
Therapeutic Solutions International (TSOI) announced successful treatment of a Navy SEAL Veteran suffering from Chronic Traumatic Encephalopathy (CTE) using JadiCell adult stem cells. The treatment involved two injections with no adverse events reported. The company is committed to clinical trials, having received Phase III clearance for COVID-19 ARDS and planning a Phase I/II trial for CTE. The initiative provides pro bono access to military personnel. The CEO expressed pride in supporting veterans amid rising suicide rates, emphasizing the urgent need for new therapeutic strategies.